AffyImmune Therapeutics to Present Poster at 2024 American Association for Cancer Research Annual Meeting
AffyImmune Therapeutics to Present Poster at 2024 American Association for Cancer Research Annual Meeting
NATICK, Mass.–(BUSINESS WIRE)–#AACR2024—AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today that it will present an abstract in a poster session at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, 2024, in San Diego, California. Presented findings will highlight research applying the affinity-tuned, trackable, ICAM-1 targeting CAR T cell therapy AIC100 to additional solid tumor types where there is significant unmet medical need.
Details of the poster presentation are as follows:
Poster Title: AIC100 CAR-T cells targeting ICAM-1 are efficacious against solid tumors in xenograft mouse models of Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer (CC).
Date and Time: Tuesday Apr 9, 2024, 9:00 AM – 12:30 PM
Presenting Author: Alyssa Birt, AffyImmune Therapeutics
Session Category: Immunology
Session Title: Adoptive Cell Therapies 3: CAR-T Cells
Location: Poster Section 2, Poster Board Number: 16
Published Abstract Number: 4007
About AffyImmune Therapeutics
AffyImmune is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR-T cell therapies to transform the lives of patients with cancer. The Company’s proprietary technology utilizing ICAM1/LFA-1 interaction can potentially address all critical CAR-T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR-T cells. Its lead candidate, AIC100, is a ICAM1-directed CAR-T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ICAM-1 in oncologic indications with high unmet medical need. AffyImmune is based in Natick, MA. For more information, visit www.affyimmune.com.
Contacts
Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744